Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.
Surmodics, Inc. (SRDX) generates news as a provider of medical device technologies, vascular intervention devices, and in vitro diagnostic components. Company announcements frequently highlight developments in its performance coating technologies for intravascular devices, its Pounce™ Thrombectomy Platform, and its SurVeil™ drug-coated balloon (DCB), as well as financial results and corporate transactions.
Investors and industry observers following Surmodics news can expect updates on clinical and real-world evidence for its vascular intervention products. The company has reported data from the PROWL registry, an open-label, multi-center U.S. registry evaluating the Pounce Thrombectomy Platform for non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. News coverage includes analyses of 160-patient cohorts with symptomatic limb ischemia and sex-specific outcomes, presented at conferences such as the VIVA Vascular Symposium and the TCT Symposium.
Surmodics also issues press releases on product milestones, including the commercial release and early clinical use of the Pounce XL Thrombectomy System, which is intended for thrombus and embolus removal in peripheral arteries of larger diameters. Additional news has covered publication of the TRANSCEND clinical trial, which evaluated the SurVeil DCB in femoropopliteal arterial disease.
Financial news from Surmodics includes quarterly earnings releases, segment revenue trends in its Medical Device and In Vitro Diagnostics businesses, and updates to fiscal year guidance. The company has also reported on a pending and subsequently completed acquisition by an affiliate of GTCR LLC, including regulatory actions, court decisions related to the Federal Trade Commission’s attempt to block the transaction, and steps toward delisting from Nasdaq and transitioning to private ownership.
By monitoring this news feed, readers can track Surmodics’ product performance data, regulatory and legal developments, and financial disclosures as the company advances its mission to improve the detection and treatment of disease.
Surmodics, Inc. (NASDAQ: SRDX) will release its fourth quarter and fiscal year 2022 financial results on November 9, 2022, before market opens. A live webcast and conference call will take place at 7:00 a.m. CT on the same day, discussing the financial outcomes and company achievements. Investors can access the call via their website or by dialing in. An audio replay will be available until November 23, 2022. Surmodics specializes in surface modification technologies for medical devices and diagnostic tests, focusing on clinical needs.
Surmodics, Inc. (NASDAQ:SRDX) announced that findings from the TRANSCEND clinical trial will be shared at the Vascular InterVentional Advances (VIVA) conference on November 1, 2022. Dr. Kenneth Rosenfield will present 24-month data on the efficacy and safety of the SurVeil drug-coated balloon (DCB) compared to IN.PACT Admiral DCB. Initial results at 12 months indicated non-inferiority for SurVeil with a lower drug dose. Surmodics has an agreement with Abbott (NYSE: ABT) for commercialization rights.
Surmodics, Inc. (Nasdaq: SRDX) announced a new five-year credit agreement with MidCap Financial, offering up to $100 million in term loans and $25 million in revolving credit. CEO Gary Maharaj emphasized improved capital access on favorable, non-dilutive terms. The company initially drew $25 million from the term loan and $5 million from the revolving credit, boosting its cash balance by $19.5 million. Interest-only payments for the term loan are set for the first four years. Total interest expenses are expected to be approximately $3.4 million in fiscal 2023.
Surmodics, Inc. (NASDAQ:SRDX) announced promising 6-month results from the SWING study of its Sundance™ Sirolimus drug-coated balloon (DCB) at the Amputation Prevention Symposium in Lugano, Switzerland. The study reported an 88.5% primary patency rate and a Late Lumen Loss (LLL) of 1.0 mm across 35 lesions, indicating sustained efficacy. No major amputations or perioperative deaths were observed, and only one major re-intervention was needed among participants. The Sundance DCB employs innovative coating technology to enhance sirolimus delivery, aiming to reduce restenosis.
Surmodics, Inc. (NASDAQ:SRDX) announced the presentation of 6-month data from the SWING Trial, evaluating the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon. This first-in-human study will be presented by Professor Ramon Varcoe on October 11 at the Amputation Prevention Symposium in Switzerland. The Sundance Balloon aims to offer a new treatment for patients with Critical lower limb ischemia, potentially improving quality of life and reducing surgical intervention needs. The device is currently for investigational use only and not for sale.
Surmodics, Inc. (NASDAQ: SRDX) announced a presentation at the Gilmartin Emerging Growth Company Showcase on
Surmodics, Inc. (Nasdaq: SRDX) reported fiscal 2022 third-quarter revenues of $24.9 million, marking a 4% year-over-year increase. The company experienced a GAAP loss per share of $(0.41) and a non-GAAP loss per share of $(0.34). Medical Device revenue rose to $17.5 million, a 5% increase, while In Vitro Diagnostics revenue reached $7.3 million, up 3%. Surmodics revised its revenue guidance for fiscal 2022 to $97 million to $99 million, reflecting soft customer demand, while EPS guidance improved to $(1.50) to $(1.35) due to strong year-to-date results.
Surmodics, Inc. (NASDAQ: SRDX) will host a live webcast for its Q3 fiscal 2022 conference call on July 27 at 7:30 a.m. CT. An earnings release will precede the market's opening. CEO Gary Maharaj and CFO Tim Arens will discuss financial results and company achievements. The call will include access via a dedicated link and phone number. An audio replay will be available from 10:30 a.m. CT on July 27 to August 3. Surmodics focuses on medical device surface modification and aims to improve disease detection and treatment.
Surmodics, Inc. (Nasdaq: SRDX) will present at the Jefferies 2022 Healthcare Conference on June 9, 2022, at 3:30 p.m. ET. CEO Gary Maharaj and CFO Tim Arens will discuss the company's innovative medical device and diagnostic technologies. A live audio webcast of this event can be accessed here or through the Investor Relations section of their website. The presentation will be archived for 90 days post-event. Surmodics focuses on enhancing disease detection and treatment through advanced surface modification technologies.
Surmodics, Inc. (Nasdaq: SRDX) reported second-quarter fiscal 2022 results, revealing total revenue of $26.1 million, a 13% sequential increase, but down from $35 million in the prior-year quarter. Medical Device revenue declined to $18.5 million from $27.9 million year-over-year. In Vitro Diagnostics achieved a record $7.7 million. GAAP EPS was a loss of $(0.29) compared to $0.58 earnings last year. The company raised its fiscal 2022 revenue guidance to $98-$101 million and adjusted EPS guidance to a loss of $(1.70)-(1.35).